相关实验视频
Updated: Jun 29, 2025

Assessment of Vascular Regeneration in the CNS Using the Mouse Retina
Published on: June 23, 2014
端粒酶的治疗向改善了实验性冠状腺新血管化
Aman Kumar1, Yosuke Nagasaka2, Vinodhini Jayananthan1
1Department of Ophthalmology and Visual Sciences, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
端粒酶在胆管新血管化 (CNV) 中起着关键作用,这是新血管与年龄相关的黄斑变性 (nvAMD) 中导致失明的主要原因. 抑制端粒酶,特别是与抗VEGF疗法相结合,显示出治疗这种眼睛疾病的前景.
科学领域:
- 眼科医生 眼科 眼科
- 分子生物学分子生物学
- 血管新生研究研究
背景情况:
- 状新血管化 (CNV) 在新血管与年龄相关的黄斑变性 (nvAMD) 中导致失明.
- 端粒酶活性与内皮细胞增殖和瘤血管生成有关.
研究的目的:
- 调查端粒酶在CNV发展中的作用.
- 评估端粒酶抑制作为nVAMD的潜在治疗策略.
主要方法:
- 在激光诱导的CNV的小鼠模型中评估了端粒酶基因表达和活性.
- 利用了端粒酶成分 (Tert,Terc) 的遗传缺陷,一个小分子抑制剂 (BIBR 1532) 和反感性寡核酸 (ASO).
- 进行了骨髓模拟研究,并将BIBR 1532与抗VEGF治疗进行了比较,包括组合治疗.
主要成果:
- 在小鼠CNV中观察到提升的端粒酶表达和活性.
- 对Tert/Terc的遗传删除和对TERT的药理抑制显著抑制了CNV.
- 在非骨髓衍生细胞中的端粒酶活性对中枢神经病毒的发展至关重要.
- 结合BIBR 1532和抗VEGF抗体的次治疗剂量显示出对CNV的协同抑制.
结论:
- 端粒酶是 CNV 发育的关键因素,也是 nvAMD 的潜在治疗点.
- 与端粒酶抑制剂和抗VEGF药物的联合治疗为治疗神经血管眼病提供了一个有前途的策略.
更多相关视频
11:13Adenoviral Gene Therapy for Diabetic Keratopathy: Effects on Wound Healing and Stem Cell Marker Expression in Human Organ-cultured Corneas and Limbal Epithelial Cells
Published on: April 7, 2016
06:48Limbal Approach-Subretinal Injection of Viral Vectors for Gene Therapy in Mice Retinal Pigment Epithelium
Published on: August 7, 2015
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Replicative Cell Senescence
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...